Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacodynamic Biomarker Study of Sorafenib in Metastatic Renal Carcinoma

PURPOSE: Sorafenib is an antiangiogenic agent with activity in renal cancer. We conducted a randomized trial to investigate dynamic contrast magnetic resonance imaging (DCE-MRI) as a pharmacodynamic biomarker. PATIENTS AND METHODS: Patients were randomly assigned to placebo or 200 or 400 mg twice pe...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Hahn, Olwen M., Yang, Cheng, Medved, Milica, Karczmar, Gregory, Kistner, Emily, Karrison, Theodore, Manchen, Elizabeth, Mitchell, Myrosia, Ratain, Mark J., Stadler, Walter M.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2008
Matèries:
Genitourinary Cancer
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2736992/
https://ncbi.nlm.nih.gov/pubmed/18824708
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2007.15.5655
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars